TFR Capital LLC. Invests $1.84 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

TFR Capital LLC. bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,561 shares of the pharmaceutical company's stock, valued at approximately $1,837,000.

A number of other hedge funds have also recently modified their holdings of VRTX. Brighton Jones LLC lifted its holdings in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock worth $1,783,000 after buying an additional 579 shares during the period. PFG Investments LLC lifted its holdings in Vertex Pharmaceuticals by 2.5% during the fourth quarter. PFG Investments LLC now owns 1,817 shares of the pharmaceutical company's stock worth $732,000 after buying an additional 44 shares during the period. Blue Trust Inc. lifted its holdings in Vertex Pharmaceuticals by 33.0% during the fourth quarter. Blue Trust Inc. now owns 3,605 shares of the pharmaceutical company's stock worth $1,452,000 after buying an additional 894 shares during the period. Union Bancaire Privee UBP SA purchased a new stake in Vertex Pharmaceuticals during the fourth quarter worth $56,000. Finally, KBC Group NV lifted its holdings in Vertex Pharmaceuticals by 23.5% during the fourth quarter. KBC Group NV now owns 119,429 shares of the pharmaceutical company's stock worth $48,094,000 after buying an additional 22,702 shares during the period. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded up $1.99 on Thursday, hitting $447.09. 882,371 shares of the company were exchanged, compared to its average volume of 1,418,078. The stock has a market capitalization of $114.81 billion, a price-to-earnings ratio of -203.22, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $472.28 and a 200 day moving average price of $461.84. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.76 EPS. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on VRTX. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Bank of America raised their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Wolfe Research lowered Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Morgan Stanley raised their target price on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a research note on Tuesday, May 6th. Finally, Barclays raised their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 11th. Fourteen equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $515.04.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.